This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
AZNNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change IBBNegative Net Change XBIPositive Net Change BBHNegative Net Change FBTNegative Net Change BTECPositive Net Change BNTXNegative Net Change
biotechs etfs
Company News for Apr 8, 2021
by Zacks Equity Research
Companies In The News Are: QGEN, MSM, LI, GEO.
QGENNegative Net Change GEONegative Net Change MSMPositive Net Change LIPositive Net Change
auto-tires-trucks biotechs industrial-products reit
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
by Zacks Equity Research
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
AZNNegative Net Change RHHBYPositive Net Change GILDNegative Net Change MRKPositive Net Change
biotechs
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
by Zacks Equity Research
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
ALKSNegative Net Change MRKPositive Net Change RGENNegative Net Change NBRVPositive Net Change
biotechs
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma
ASYSNegative Net Change AYTUPositive Net Change CDMOPositive Net Change
biotechs finance medical
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
JNJPositive Net Change DVAXNegative Net Change GILDNegative Net Change EBSNegative Net Change ACADPositive Net Change
biotechs pharmaceuticals
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
JNJPositive Net Change DVAXNegative Net Change GILDNegative Net Change EBSNegative Net Change ACADPositive Net Change
biotechs pharmaceuticals
QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio
by Zacks Equity Research
QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.
HOLXPositive Net Change QGENNegative Net Change HRCPositive Net Change INONegative Net Change
biotechs medical
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
DVAXNegative Net Change MRKPositive Net Change GSKNegative Net Change VBIVPositive Net Change
biotechs
Find Strong Stocks to Start Q2 with New Analyst Coverage
by Benjamin Rains
One way to find potential winners is to search for companies that have landed new analyst coverage recently. And the reasoning is pretty straightforward...
IBKRNegative Net Change MPNegative Net Change CDMOPositive Net Change
biotechs finance industrial-products
Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
by Zacks Equity Research
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
MRKPositive Net Change EXELNegative Net Change BMYPositive Net Change RGENNegative Net Change
biotechs
Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up
by Zacks Equity Research
Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.
ILMNNegative Net Change XRAYNegative Net Change HOLXPositive Net Change HRCPositive Net Change
biotechs medical
Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies
by Zacks Equity Research
Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.
MRNANegative Net Change
biotechs
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
by Zacks Equity Research
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
CLDXNegative Net Change RGENNegative Net Change ACADPositive Net Change NBRVPositive Net Change
biotechs
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
by Zacks Equity Research
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
JNJPositive Net Change RGENNegative Net Change SUPNPositive Net Change TAKNegative Net Change
biotechs medical pharmaceuticals
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
by Zacks Equity Research
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
JNJPositive Net Change AZNNegative Net Change GILDNegative Net Change EBSNegative Net Change
biotechs
SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study
by Zacks Equity Research
SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.
JNJPositive Net Change PFEPositive Net Change GSKNegative Net Change
biotechs
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
REGNNegative Net Change CYDYNegative Net Change VIRPositive Net Change KLDOPositive Net Change
biotechs pharmaceuticals
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
by Zacks Equity Research
Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.
PFEPositive Net Change MRKPositive Net Change EXELNegative Net Change BMYPositive Net Change
biotechs pharmaceuticals
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
by Zacks Equity Research
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
INCYNegative Net Change RGENNegative Net Change NBRVPositive Net Change SNDXNegative Net Change
biotechs
Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout
by Zacks Equity Research
Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.
BMYPositive Net Change AMGNPositive Net Change RGENNegative Net Change NBRVPositive Net Change
biotechs
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
by Zacks Equity Research
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
INCYNegative Net Change GSKNegative Net Change BMYPositive Net Change VRTXPositive Net Change VIRPositive Net Change KLDOPositive Net Change
biotechs
7 Best Leveraged/Inverse ETFs Up 20% Plus in March
by Sweta Killa
Amid the bull and bear tug-of-war, the demand for leveraged and inverse-leveraged ETFs has increased.
RETLNegative Net Change LABDPositive Net Change NAILNegative Net Change TPORNegative Net Change DUSLNegative Net Change UTSLNegative Net Change
biotechs cloud-computing construction etfs industrial-products retail transportation utilities
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
PFEPositive Net Change MRNANegative Net Change IBBNegative Net Change BBHNegative Net Change BTECPositive Net Change
biotechs etfs
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
GILDNegative Net Change NVSPositive Net Change BMYPositive Net Change
biotechs